New Herpes Drug Adibelivir Advances to Phase 2, Targeting Unmet Needs

MUNICH, Germany – January 29, 2026 – German biotechnology firm Innovative Molecules GmbH announced today the successful completion of its Phase 1 clinical program for adibelivir, a novel oral drug for herpes simplex virus (HSV). The company is now advancing the promising antiviral candidate into Phase 2 trials, a critical step that moves it closer to potentially offering a new weapon against a virus that affects billions worldwide.

The advancement follows a series of studies demonstrating a positive safety and tolerability profile for adibelivir (also known as IM-250), paving the way for the next stage of development which will focus on the drug's effectiveness in patients with genital herpes.

"With the successful completion of our Phase 1 program, we have achieved a critical development milestone for adibelivir," said Florian Vogel, CEO of Innovative Molecules, in a statement. "This validates our clinical strategy and forms a strong foundation for transition into the next stage of clinical development."

A New Mechanism to Combat an Old Foe

Adibelivir represents a significant departure from the current standard of care for herpes infections. For decades, the primary treatments have been nucleoside analogs like acyclovir and its successor, valacyclovir. These drugs work by mimicking DNA building blocks and getting incorporated into the replicating viral DNA, ultimately halting the process. While effective for many, their limitations have become increasingly apparent.

Adibelivir, in contrast, is an oral selective helicase-primase inhibitor (HPI). This class of drugs targets a different and essential piece of the viral replication machinery. The helicase-primase complex, a trio of viral proteins, is responsible for unwinding the virus's double-stranded DNA and preparing it for copying. By inhibiting this complex, adibelivir effectively locks the viral replication engine, preventing the virus from multiplying.

This novel mechanism holds two key potential advantages. First, it offers a new line of attack against HSV strains that have developed resistance to traditional nucleoside analogs. Such resistance is a growing concern, particularly in immunocompromised patients where the virus can cause severe, persistent, and life-threatening disease. Because HPIs target a completely different viral enzyme, they are expected to be effective even when older drugs are not.

Second, preclinical data has suggested that HPIs can be exceptionally potent. Research on IM-250 in animal models showed superior efficacy compared to valacyclovir, leading to significantly higher survival rates and a more substantial reduction of the virus in vital organs. This potency could translate to better symptom control and a more profound impact on the course of the disease for patients.

Renewed Hope for Millions Living with Herpes

The need for new and improved herpes treatments is immense. According to the World Health Organization, an estimated 3.8 billion people globally have HSV-1, the virus that primarily causes oral herpes, while nearly 520 million people live with HSV-2, the main cause of genital herpes. While many infections are asymptomatic, symptomatic herpes is characterized by painful, recurring blisters and ulcers.

Beyond the physical discomfort, recurrent outbreaks can carry a significant psychological and social burden. Current suppressive therapies can reduce the frequency of these outbreaks but do not eliminate them, nor do they cure the underlying infection. The virus establishes a lifelong latent infection in nerve cells, ready to reactivate at any time. Existing drugs are ineffective against this latent virus.

For individuals with weakened immune systems, such as organ transplant recipients or those with HIV, HSV can be far more than a nuisance. In these populations, outbreaks can be more frequent, severe, and widespread, and the risk of developing drug-resistant strains is much higher. A new, potent antiviral with a different mechanism of action like adibelivir could provide a critical therapeutic option for this vulnerable and underserved patient population.

A Critical Milestone for a Focused Biotech

The transition from Phase 1 to Phase 2 is a significant de-risking event in the long and costly journey of drug development. For a clinical-stage company like Innovative Molecules, it represents a major validation of its scientific platform and lead candidate. The completed Phase 1 program was comprehensive, including single and multiple-dose studies in healthy volunteers (IM-101 and IM-102), a study on the drug's interaction with food (IM-103), and an initial study in patients with genital herpes (the Phase 1b portion of study IM-202).

Successfully navigating these initial safety trials demonstrates that the drug is well-tolerated in humans, clearing the path for the next crucial question: how well does it work? This milestone is a testament to the company's focused strategy on developing transformative therapies for herpes infections, an area where major innovation has been slow to arrive.

Navigating a Competitive Landscape

Innovative Molecules is not alone in recognizing the opportunity to improve upon decades-old herpes treatments. The development of helicase-primase inhibitors is an active area of research, with a handful of other companies pursuing drugs with a similar mechanism. This competition underscores the scientific community's belief in the potential of HPIs. According to one infectious disease expert not involved with the company, the development of this new drug class is an "important alternative therapy" for patients, especially those who have exhausted other options.

Beyond HPIs, the broader landscape includes research into therapeutic vaccines, gene-editing technologies aiming to eliminate the latent virus, and other novel small molecules targeting different viral processes. This flurry of activity signals a potential paradigm shift in how herpes is managed in the coming years.

With adibelivir now entering the efficacy-focused Phase 2a part of the IM-202 trial, the focus will shift squarely to its performance in treating active genital herpes. Researchers and clinicians will be closely watching for data on how effectively the drug reduces viral shedding, shortens healing time, and alleviates symptoms compared to a placebo. The results from this next phase will be pivotal in determining adibelivir's future and its potential place in the evolving arsenal of antiviral therapies.